Related Experiment Video
Updated: Aug 16, 2026

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
Published on: September 19, 2019
ETODA: Automatic three-dimensional error tolerance grid generation for dosage adaptation in precision medicine
Lin Du1, Myriam Briki2, Thierry Buclin3
1Bio/CMOS Interfaces Laboratory (BCI), École Polytechnique Fédérale de Lausanne, 2002 Neuchâtel, Switzerland; School of Engineering and Management Vaud, HES-SO University of Applied Sciences and Arts Western Switzerland, 1401 Yverdon-les-Bains, Switzerland.
A new framework, ETODA, evaluates how measurement errors in point-of-care drug monitoring affect precision dosing decisions. It quantizes dosage adaptation robustness, ensuring safer and more effective model-informed precision dosing (MIPD).
Area of Science:
- Pharmacokinetics and Pharmacodynamics
- Computational Biology
- Clinical Pharmacology
Background:
- Model-informed precision dosing (MIPD) uses drug measurements for individualized regimens.
- Point-of-care (POC) technologies may introduce measurement uncertainty compared to lab assays.
- Existing frameworks lack tools to assess how measurement inaccuracies impact dosing decisions and outcomes.
Purpose of the Study:
- To develop and validate a computational framework, ETODA (error tolerance of dosage adaptation), for quantifying the robustness of dosage decisions under measurement uncertainty.
- To systematically evaluate how inaccuracies in drug concentration measurements propagate to dosage adaptation and affect therapeutic outcomes at different sampling times.
Main Methods:
- ETODA integrates population pharmacokinetic (popPK) models, patient covariates, Bayesian estimation, and Monte Carlo simulations.
- It constructs 3D error-tolerance grids to map measured vs. true concentrations, sampling time, and therapeutic risk.
- The framework was applied to imatinib and vancomycin using simulated steady-state concentration ranges.
Main Results:
- ETODA revealed drug-specific responses to measurement discrepancies and the impact of sampling time on therapeutic classification.
- For imatinib, peak sampling at 4h maximized therapeutic classification (52.24%), while 24h sampling increased inefficacy alarms (53.47%).
- For vancomycin, AUC/MIC monitoring outperformed trough monitoring in achieving therapeutic targets and reducing alarms.
Conclusions:
- ETODA offers a robustness-evaluation layer for popPK and MIPD workflows, mapping measurement error to dose decisions and risk classifications.
- This framework supports more robust MIPD and guides the development of POC monitoring technologies for improved precision dosing.
- It enhances the safety and efficacy of precision dosing by accounting for measurement uncertainty.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
